The estimated Net Worth of Andrew Hirsch is at least $1.3 million dollars as of 30 August 2023. Mr Hirsch owns over 7,500 units of C4 Therapeutics stock worth over $696,636 and over the last 8 years he sold CCCC stock worth over $0. In addition, he makes $607,958 as CEO et Pres & Director at C4 Therapeutics.
Mr has made over 8 trades of the C4 Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of CCCC stock worth $45,000 on 30 August 2023.
The largest trade he's ever made was exercising 12,500 units of C4 Therapeutics stock on 30 January 2023 worth over $75,000. On average, Mr trades about 1,931 units every 42 days since 2016. As of 30 August 2023 he still owns at least 116,106 units of C4 Therapeutics stock.
You can see the complete history of Mr Hirsch stock trades at the bottom of the page.
Andrew J. Hirsch is the CEO, Pres & Director at C4 Therapeutics.
As the CEO et Pres & Director of C4 Therapeutics, the total compensation of Mr Hirsch at C4 Therapeutics is $607,958. There are 1 executives at C4 Therapeutics getting paid more, with Dr. Adam S. Crystal M.D., Ph.D. having the highest compensation of $661,550.
Mr Hirsch is 50, he's been the CEO et Pres & Director of C4 Therapeutics since . There are 3 older and 2 younger executives at C4 Therapeutics. The oldest executive at C4 Therapeutics, Inc. is Dr. Kenneth C. Anderson M.D., Ph.D., 70, who is the Co-Founder, Independent Director & Member of Scientific Advisory Board.
Andrew's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC.,, 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 4 years, insiders at C4 Therapeutics have traded over $12,678,122 worth of C4 Therapeutics stock and bought 27,275 units worth $336,287 . The most active insiders traders include Marc A Cohen, Alain J Cohen et Elena Prokupets. On average, C4 Therapeutics executives and independent directors trade stock every 17 days with the average trade being worth of $56,874. The most recent stock trade was executed by Andrew Hirsch on 30 August 2023, trading 7,500 units of CCCC stock currently worth $45,000.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics executives and other stock owners filed with the SEC include: